Five Things Must Know for Joenja (Leniolisib)!

Joenja (Leniolisib) is changing the landscape for Activated PI3K Delta Syndrome (APDS)—a rare primary immunodeficiency caused by overactive immune signaling. As the first and only FDA-approved therapy specifically targeting the PI3K delta pathway, Joenja goes beyond managing infections—it addresses the root cause of the disease at the molecular level.

In this episode, Dr. Lin, a board-certified allergist and immunologist, explains the five key things every patient and caregiver should know about Joenja: its indication, mechanism of action, dosing, pregnancy and drug-interaction precautions, and safety profile.

💡 Want to understand how Joenja differs from traditional treatments? This video breaks it down clearly and simply—science-based, clinically concise, and made for patients and caregivers.

📌 Watch Now & Learn the Truth About Joenja!

📢 Subscribe for more science-based medical insights, and turn on notifications so you never miss an update!

💬 Do you or someone you know live with APDS or other primary immunodeficiencies? Share your thoughts or experiences in the comments—we’d love to hear from you!

🔗 Related Videos & Resources:
💡 Three Secrets Need to Know about Joenja (Leniolisib)!
👉 Coming up.

#Joenja #Leniolisib #APDS #ActivatedPI3KDeltaSyndrome #PrimaryImmunodeficiency #PI3KDelta #PrecisionMedicine #FDAApproved #RareDiseaseTreatment #Immunology #AllergyAndImmunology #DoctorExplains #Medician #MedicianChannel #MedicalBreakthrough #PatientEducation #RareDiseaseAwareness #Immunotherapy #MedicianAllergy